|
| |
AventisAventis is dedicated to improving life through the discovery and development of innovative pharmaceutical products.
We offer a range of patented prescription drugs to treat patients with serious diseases and have leading positions in a number of therapeutic areas, including respiratory/allergy, cardiology/thrombosis, oncology and diabetes. We are also world leaders in the areas of human vaccines and therapeutic proteins.
Aventis has two products with sales of more than € 1 billion and two additional products with sales of more than € 500 million that are fast approaching blockbuster status. Several other products have significant potential, and we are focusing our marketing and sales activities on this group of “strategic brands.”
Our pipeline is full with a number of therapeutic innovations in development, including compounds for the treatment of diabetes and cancer as well as respiratory and cardiovascular diseases. More than 5,000 scientists at sites in France, Germany, Japan and the United States are expanding our leading position in the discovery and development of new drugs.
Aventis is dedicated to creating and delivering products of unquestionable quality that enable people to live longer, healthier and more active lives. In this spirit, we encourage our employees to care for each other’s well being and protect the environment in all aspects of their lives. We are committed to the principles of sustainable development, which is demonstrated by our participation in the U.N. Global Compact.
Aventis was created through the December 1999 business combination of Hoechst and Rhône-Poulenc. We are transforming Aventis into a pure pharmaceutical company through the divestiture of the Aventis CropScience and Aventis Animal Nutrition businesses as well as the remaining industrial activities. Along with our pharmaceutical business, Aventis will retain a 50% stake in the animal health business Merial, a joint venture with Merck & Co. (accounted for using the equity method).
| Contact Details: |
| Cedex 9 |
| Strasbourg |
| FR |
| 67917 |
| United Kingdom |
| Tel: | +33-388-99-1100 |
| Fax: | 33 (0) 3 8899 1375 |
| Email: | Arvind.Sood@aventis.com |
| WWW: | www.aventis.com/
|
|
Loading...
|
Recent Publications by Aventis: |  |
No replication of genetic association between candidate polymorphisms and Alzheimer's disease.
Alzheimer's disease is a genetically complex disorder, for which new... | 6th November, 2009
| Biological Sciences Department, sanofi-aventis Recherche et Developpement,
| Neurobiol Aging. 2009 Nov 2.
DOI Direct Link |
A robust assay measuring GLUT4 translocation in rat myoblasts overexpressing GLUT4-myc and AS160_v2.
Muscle and fat cells translocate GLUT4 (glucose transporter 4) to the... | 27th October, 2009
| Sanofi-Aventis Deutschland, 65926 Frankfurt am Main, Germany.
| Anal Biochem. 2009 Oct 23.
DOI Direct Link |
Discovery of covalent inhibitors for MIF tautomerase via cocrystal structures with phantom hits from virtual screening.
Biochemical and X-ray crystallographic studies confirmed that... | 20th October, 2009
| Discovery Research, sanofi-aventis, Bridgewater, NJ 08807, USA.
| Bioorg Med Chem Lett. 2009 Dec 1;19(23):6717-20. Epub 2009 Oct 1.
DOI Direct Link |
Antihypertensive drug therapy and blood pressure control in men and women: an international perspective.
Cardiovascular death represents the single largest cause of mortality in... | 3rd October, 2009
| [1] Medical Faculty Carl Gustav Carus, Institute for Clinical
| J Hum Hypertens. 2009 Oct 1.
DOI Direct Link |
Effectiveness of mechanochemical treatment with cyclodextrins on increasing solubility of glimepiride.
We investigated the enhancement of the solubility of glimepiride (GLM), a... | 19th September, 2009
| Sanofi-Aventis K.K, Tokyo, Japan.
| Pharmazie. 2009 Jun;64(6):390-4.
|
→View more Aventis research publications. |
Press Releases on Aventis:
|
 |
| Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013 |
20th November, 2009 |
Reportlinker |
NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013
|
| VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests |
19th November, 2009 |
|
SAN DIEGO, November 19 /PRNewswire/ -- Accumetrics, Inc., developer of the VerifyNow System, the first
point-of-care method for measuring platelet reactivity, announces that its
market-leading
|
| Reportlinker Adds Antibiotics - Global Trends |
18th November, 2009 |
Reportlinker |
NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Antibiotics - Global Trends
http://www.reportlinker.com/p0164263
|
| Reportlinker Adds Anticoagulants - A Global Market Review |
18th November, 2009 |
Reportlinker |
NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Anticoagulants - A Global Market Review
http://www.reportlinker.com
|
| American Heart Association Late-breaking Clinical Trial Report: Risks of Anemia Drug Outweigh Benefits in Cardiovascular Disease Patients With Diabetes and Kidney Disease |
16th November, 2009 |
American Heart Association |
Study highlights:
- Risks of an anemia drug appear to outweigh its benefits among diabetic patients with kidney disease, anemia and a history of cardiovascular disease or stroke.
- This first large,
|
Aventis Patents: |  |
| US Patent No. | Title |
| 7550597 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
| 7566720 | 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives
|
| 7566736 | Substituted indoles, compositions containing them, method for the production thereof and their use
|
| 7569567 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-B]indole-1-carboxamide derivatives, their preparation and therapeutic use
|
| 7569582 | Aminotropane derivatives, preparation thereof and therapeutic use thereof
| →View more Aventis patents. |
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 277 individuals from Aventis using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 454 times since April 2007, the link to the organisation's website has been followed 63 times Recent Search Terms used to find this page: aventis com | . Search for more companies in Strasbourg Search for more companies in FR This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Aventis |
